|Bid||75.80 x 3100|
|Ask||78.64 x 1300|
|Day's range||76.91 - 77.43|
|52-week range||75.73 - 94.19|
|PE ratio (TTM)||23.71|
|Forward dividend & yield||2.98 (3.80%)|
|1y target est||88.16|
May.16 -- Novartis AG’s top lawyer, Felix Ehrat, became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Donald Trump’s attorney Michael Cohen. Bloomberg's Drew Armstrong reports on "Bloomberg Markets: Balance of Power."
Biotech companies and pharmacy benefit managers defied the overall market trend, despite more noise about President Trump's drug plan.
Cohen is under federal criminal investigation for, among other things, a $130,000 payment to the porn star Stormy Daniels in exchange for her silence about an alleged affair with President Trump in 2006.
Aimovig from Amgen and Novartis could become a $1 billion to $2 billion business in five years, say one Wall Street analyst.
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
The FDA has approved a new drug called Aimovig that is touted as the first treatment designed specifically to prevent migraines.
A blockbuster story about the whistleblower who revealed President Donald Trump’s personal lawyer received payments from various companies has placed attention on a fairly obscure unit with the Treasury Department that’s at the heart of regulating the financial system. The New Yorker’s Ronan Farrow interviewed someone he called a “law-enforcement official” who leaked, per the report, after not being able to find two suspicious-activity reports on Michael Cohen, who received big payments from AT&T, Novartis and Korea Aerospace Industries.
On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.
On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.
In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.
Shares of drugmakers Amgen Inc. and Novartis AG rose in after-hours trading Thursday after jointly announcing FDA approval of Aimovig, a first-of-its-kind treatment for migraines. In a statement, Novartis said the Federal Drug Administration approved Aimovig's use for the preventive treatment of migraines in adults. "Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine," Novartis Chief Executive Paul Hudson said in the statement.
TRENTON, N.J. (AP) — U.S. drug regulators are publicizing information on brand-name drugmakers that use what government officials call "gaming tactics" to block cheaper copycat versions.
Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.
ZURICH——A top executive at Swiss drugmaker Novartis AG is stepping down amid the controversy over payments that corporations made to a company owned by U.S. President Donald Trump’s longtime personal lawyer . Novartis said Wednesday that general counsel Felix Ehrat, 61 years old, is retiring from the company in connection with $1.2 million in payments it made over the course of a year to Michael Cohen’s shell company, Essential Consultants LLC. It was the second high-profile departure in less than a week in relation to payments to the company.
Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.
A law enforcement official leaked a suspicious activity report about Trump lawyer Michael Cohen and payments by Novartis and AT&T to his Essential Consultants company, The New Yorker reports.
Although other companies, including AT&T, also paid Mr. Cohen for his services, Novartis is distinguished for likely having paid more than any of the others, and it has drawn the attention of prosecutors at home. Novartis is a Basel-based multinational pharmaceutical company that makes a number of drugs, including treatments for cancer, heart conditions, and autoimmune diseases.
Novartis AG’s top lawyer, Felix Ehrat, became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Donald Trump’s attorney Michael Cohen. Bloomberg's ...
Joseph Jimenez, the former chief executive of Novartis, has an explanation for why the Swiss pharmaceutical lavished President Donald Trump’s personal lawyer Michael Cohen with a $1.2 million consulting contract. The hiring of Cohen by Novartis (NVS) , AT&T Inc. (XNYS:T) and Korea Aerospace Industries — revealed by the lawyer of the adult-film star who has alleged having an affair with Trump — has set off a firestorm in Washington and opened up the companies to potential legal liability.
When Michael Cohen showed up at Novartis AG last year proposing to help the drugmaker navigate the Donald Trump administration, it sounded like a promising opportunity. Cohen had, after all, served as an attorney for Trump and had close ties to the new president. It didn’t take long for Novartis to conclude Cohen was full of hot air.
Novartis's top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. The contract with Michael Cohen's Essential Consultants, the same firm used to pay porn star Stormy Daniels, has distracted Novartis's efforts to improve its image after a series of missteps. Current CEO Vas Narasimhan also said the contract was a major mistake at a meeting with investors in Basel on Wednesday and said Novartis was developing a principles-, not rules-based system to help avert corruption and guide employees' behaviour.
Novartis's (NOVN.S) top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. The contract with Michael Cohen's Essential Consultants, the same firm used to pay porn star Stormy Daniels, has distracted Novartis's efforts to improve its image after a series of missteps. Current CEO Vas Narasimhan also said the contract was a major mistake at a meeting with investors in Basel on Wednesday and said Novartis was developing a principles-, not rules-based system to help avert corruption and guide employees' behavior.